CT-P47与参照托珠单抗治疗类风湿关节炎的疗效与安全性:随机、阳性对照、双盲III期研究32周结果,含从参照托珠单抗转换为CT-P47的8周数据
这项双盲III期研究将471例类风湿关节炎患者随机分配接受CT-P47或EU批准的参照托珠单抗(8 mg/kg每4周)治疗至第20周,第24周给药前将参照托珠单抗组再随机分为继续参照托珠单抗或转换为CT-P47。第12周DAS28-ESR变化估计差值为-0.01(95%CI -0.26, 0.24),第24周为-0.10(90%CI -0.30, 0.10),均在预设等效界值内,至第32周次要疗效、药代动力学和总体安全性可比。
要点
- 第12周DAS28-ESR变化估计差值-0.01(95%CI -0.26, 0.24),95%CI在预设等效界值(-0.6, 0.6)内。
- 第24周DAS28-ESR变化估计差值-0.10(90%CI -0.30, 0.10),90%CI在预设等效界值(-0.6, 0.5)内。
- 至第32周次要疗效、药代动力学和总体安全性在CT-P47与参照托珠单抗组间可比,包括从参照托珠单抗转换为CT-P47后。
核心结论
- CT-P47与参照托珠单抗在成人类风湿关节炎中确定疗效等效,药代动力学、安全性和免疫原性特征可比,包括从参照托珠单抗转换为CT-P47后。
研究设计与样本
- 双盲III期研究,将类风湿关节炎患者按1:1随机分配接受CT-P47或EU批准的参照托珠单抗(8 mg/kg每4周)至第20周(治疗期1)。
- 第24周给药前,参照托珠单抗组患者按1:1再随机分配继续参照托珠单抗或转换为CT-P47;CT-P47组继续CT-P47至第48周(治疗期2,8 mg/kg每4周)。
- 治疗期1共随机471例患者(CT-P47组234例,参照托珠单抗组237例)。
主要发现
- 第12周DAS28-ESR变化估计治疗差值为-0.01(95%CI -0.26, 0.24),95%CI在预设等效界值(-0.6, 0.6)内。
- 第24周DAS28-ESR变化估计治疗差值为-0.10(90%CI -0.30, 0.10),90%CI在预设等效界值(-0.6, 0.5)内。
- 至第32周次要疗效终点、药代动力学和总体安全性在组间可比。
关键数值与推荐
- 双主要终点为第12周和第24周DAS28(基于ESR)较基线的平均变化。
- 疗效等效判定标准:第12周协方差分析(ANCOVA)的95%CI在预设等效界值(-0.6, 0.6)内,或第24周采用多重插补的ANCOVA的90%CI在预设等效界值(-0.6, 0.5)内。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To demonstrate efficacy equivalence of CT-P47 and EU-approved reference tocilizumab (r-TCZ) in patients with rheumatoid arthritis (RA). METHODS: This double-blind, phase III study randomised (1:1) patients to receive CT-P47 or r-TCZ (8 mg/kg) every 4 weeks until week 20 during treatment period (TP) 1. Prior to week 24 dosing, patients receiving r-TCZ were randomised (1:1) to continue r-TCZ or switch to CT-P47; patients receiving CT-P47 continued CT-P47 (TP2, 8 mg/kg every 4 weeks until week 48). The dual primary endpoints (for different regulatory requirements) were mean changes from baseline in Disease Activity Score in 28 joints (DAS28; erythrocyte sedimentation rate (ESR)) at week 12 and week 24. Efficacy equivalence was determined if CIs for the treatment difference were within predefined equivalence margins: (95% CI -0.6, 0.6 (analysis of covariance (ANCOVA)) at week 12 or 90% CI -0.6, 0.5 (ANCOVA with multiple imputation) at week 24). Additional efficacy, pharmacokinetic (PK) and safety endpoints, including immunogenicity, were investigated. Findings up to week 32 are presented. RESULTS: In TP1, 471 patients were randomised (234 CT-P47; 237 r-TCZ). The 95% and 90% CIs for the estimated treatment differences were contained within the predefined equivalence margins; the estimated difference in DAS28-ESR at week 12 was -0.01 (95% CI -0.26, 0.24) and at week 24 was -0.10 (90% CI -0.30, 0.10). Secondary efficacy endpoints, PKs and overall safety were comparable between groups up to week 32. CONCLUSIONS: Efficacy equivalence, alongside comparable PK, safety and immunogenicity profiles, was determined between CT-P47 and r-TCZ in adults with RA, including after switching from r-TCZ to CT-P47.
引用
- Smolen JS, Trefler J, Racewicz A, et al. Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47. RMD Open. 2024. PMID: 39424404. doi:10.1136/rmdopen-2024-004514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。